Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Receptor Antagonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    319 result(s) found for: Receptor Antagonist. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-005707-42 Sponsor Protocol Number: A090624 Start Date*: 2007-07-23
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury
    Medical condition: Severe Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060690 Traumatic brain injury LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001193-28 Sponsor Protocol Number: AMB-320/321-E Start Date*: 2005-11-08
    Sponsor Name:Myogen, Inc
    Full Title: ARIES-320/321-E “A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321"
    Medical condition: Pulmonary Arterial Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000715-71 Sponsor Protocol Number: CADET-PAD Start Date*: 2021-07-18
    Sponsor Name:Jagiellonian University Medical College
    Full Title: The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatm...
    Medical condition: Occlusive atherosclerosis in patients treated endovascularly due to ischemia of the lower limbs in the course of obstructive artery disease.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10067825 Peripheral arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023479-24 Sponsor Protocol Number: 01/2010 Start Date*: 2011-02-03
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Effect of Interleukin-1 receptor antagonist on insulin sensitivity in subjects with type 1 diabetes mellitus.
    Medical condition: diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023849-30 Sponsor Protocol Number: CSCAbrein&cognitie1-04 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Amsterdam
    Full Title: The effects of MR and GR blockade on the reconsolidation and extinction of fear memories
    Medical condition: Fear conditioning acquisition, reconsolidation and extinction in healthy male subjects.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003064-36 Sponsor Protocol Number: DEF_Version_1.2 Start Date*: 2015-11-10
    Sponsor Name:Vienna Institute for Research in Ocular Surgery
    Full Title: Impact of selective alpha 1A receptor antagonists on the pupil size after instillation of tropicamide 0.5% and phenylephrine 10%
    Medical condition: Impact of selective alpha 1A receptor antagonists on the pupil size after instillation of tropicamide 0.5% and phenylephrine 10%
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003367-40 Sponsor Protocol Number: 2007/049/HP Start Date*: 2009-03-03
    Sponsor Name:CHU de Rouen
    Full Title: Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteers
    Medical condition: The aim is to measure plasma aldosterone and cortisol concentrations in basal conditions and in response to different stimulation tests of the adrenal function
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000812-29 Sponsor Protocol Number: AMB 320 Start Date*: 2005-09-21
    Sponsor Name:Myogen, Inc.
    Full Title: Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037400 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000362-39 Sponsor Protocol Number: CSPP100A2243 Start Date*: 2005-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an a...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-015410-22 Sponsor Protocol Number: AMACE Start Date*: 2010-04-30
    Sponsor Name:Medizinische Fakultaet der Technischen Universitaet Muenchen
    Full Title: A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant
    Medical condition: The study objective is to assess the efficacy and safety of the Bradykinin-2 (BK-2) receptor antagonist Icatibant compared to a historic group of 47 patients with ACE inhibitor induced angioedema w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019688-12 Sponsor Protocol Number: abchits2010 Start Date*: 2010-10-18
    Sponsor Name:Friedrich-Schiller University Jena, Clinic for Internal Medicine I
    Full Title: Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjun...
    Medical condition: Up to 60 patients with stable angina pectoris and planned PCI at the University Clinic of Jena are randomly assigned to the glycoprotein IIb/IIIa receptor antagonist abciximab or placebo. Randomisa...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065608 Percutaneous coronary intervention LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005402-65 Sponsor Protocol Number: IIBSP-ANA-2013-163 Start Date*: 2015-01-19
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids
    Medical condition: Inflammation in periarticular structures in patients refractory to NSAIDs and / or corticosteroids.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019660-36 Sponsor Protocol Number: Anakinra1 Start Date*: 2010-12-07
    Sponsor Name:UMC St Radboud
    Full Title: The effect of interleukin-1 receptor antagonist on insulin secretion
    Medical condition: Beta-cell dysfunction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052341 Impaired insulin secretion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000189-12 Sponsor Protocol Number: ABR43234 Start Date*: 2013-03-14
    Sponsor Name:University Medical Centre Nijmegen
    Full Title: Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular formation of adenosine
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003981-42 Sponsor Protocol Number: 2012.2708 Start Date*: 2014-10-20
    Sponsor Name:University Medical Center Groningen [...]
    1. University Medical Center Groningen
    2. VUMC
    Full Title: Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients
    Medical condition: Estrogen receptor positive metastatic breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000701-61 Sponsor Protocol Number: BIRD-1 250705 Start Date*: 2005-11-29
    Sponsor Name:University College London
    Full Title: An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis
    Medical condition: Scleroderma renal crisis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003131-38 Sponsor Protocol Number: DOPA2016 Start Date*: 2017-06-23
    Sponsor Name:TARGID, KU Leuven
    Full Title: The effect of chlorpromazine (Largactil), a dopamine type 2-(D2-) receptor antagonist, on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled study
    Medical condition: Increased esophageal sensitivity in refractory gastro-esophageal reflux disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002154-36 Sponsor Protocol Number: CIGE025F1301 Start Date*: 2019-02-13
    Sponsor Name:Novartis Pharma KK
    Full Title: A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled...
    Medical condition: Severe Japanese cedar pollinosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036020 Pollinosis LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016139-36 Sponsor Protocol Number: V1,11.05.2009 Start Date*: 2009-12-28
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Kinder-und Jugendheilkunde
    Full Title: The AT1 receptor antagonist losartan for the prevention of excessive aortic root dilatation in children and adolescents with Marfan syndrom
    Medical condition: Marfan-Syndrom
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006042-41 Sponsor Protocol Number: NC3-project Start Date*: 2006-05-15
    Sponsor Name:Karolinska Institutet
    Full Title: Local treatment of craniomandibular myofascial pain with the 5-HT3 receptor antagonist granisetron. A randomized and double-blind study.
    Medical condition: Craniomandibular myalgia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 10:21:51 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA